Tourette syndrome, Relmada
Hosted on MSN3m
Relmada acquires Tourette’s therapy rights from AsarinaRelmada Therapeutics has acquired complete worldwide ownership rights to Sepranolone from Sweden-based Asarina Pharma.
Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...
Relmada Therapeutics (RLMD) announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid, from Asarina Pharma AB, being developed ...
Relmada Therapeutics, Inc. has recently received a notice from the Nasdaq Stock Market indicating that the company’s security did not maintain a minimum bid price of $1 per share for the 30 ...
CORAL GABLES, Fla., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a late-stage biotechnology company ...
Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.
Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report) saw a large decline in short interest during the month of January.As of January 15th, there was short interest totalling 1,250,000 ...
In a challenging year for Relmada Therapeutics (NASDAQ:RLMD), the company's stock has plummeted to a 52-week low, trading at just $0.34. According to InvestingPro data, the company maintains a strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback